Insider Buying: Charles River Laboratories International, Inc. (NYSE:CRL) COO Buys $249,249.82 in Stock

Charles River Laboratories International, Inc. (NYSE:CRL) COO Birgit Girshick purchased 1,514 shares of the company’s stock in a transaction dated Thursday, February 20th. The stock was bought at an average price of $164.63 per share, with a total value of $249,249.82. Following the completion of the transaction, the chief operating officer now directly owns 55,058 shares of the company’s stock, valued at approximately $9,064,198.54. This represents a 2.83 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Charles River Laboratories International Stock Performance

NYSE:CRL opened at $163.11 on Monday. The firm has a market capitalization of $8.34 billion, a PE ratio of 1,087.39, a price-to-earnings-growth ratio of 4.54 and a beta of 1.37. The business’s fifty day moving average price is $172.84 and its 200 day moving average price is $188.00. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.41 and a quick ratio of 1.14. Charles River Laboratories International, Inc. has a 12 month low of $150.79 and a 12 month high of $275.00.

Charles River Laboratories International (NYSE:CRL) last posted its earnings results on Wednesday, February 19th. The medical research company reported $2.66 EPS for the quarter, beating the consensus estimate of $2.50 by $0.16. The firm had revenue of $1 billion for the quarter, compared to analyst estimates of $983.63 million. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. Charles River Laboratories International’s revenue for the quarter was down 1.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.46 earnings per share. On average, sell-side analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Institutional Trading of Charles River Laboratories International

Hedge funds and other institutional investors have recently made changes to their positions in the company. Versant Capital Management Inc increased its position in shares of Charles River Laboratories International by 1,071.4% during the fourth quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock worth $30,000 after purchasing an additional 150 shares in the last quarter. Assetmark Inc. increased its position in shares of Charles River Laboratories International by 1,153.3% during the third quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock worth $37,000 after purchasing an additional 173 shares in the last quarter. Pinnacle Bancorp Inc. increased its position in shares of Charles River Laboratories International by 52.0% during the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock worth $35,000 after purchasing an additional 65 shares in the last quarter. Optiver Holding B.V. acquired a new stake in shares of Charles River Laboratories International during the fourth quarter worth about $37,000. Finally, GeoWealth Management LLC increased its position in shares of Charles River Laboratories International by 311.5% during the fourth quarter. GeoWealth Management LLC now owns 251 shares of the medical research company’s stock worth $46,000 after purchasing an additional 190 shares in the last quarter. Institutional investors and hedge funds own 98.91% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently commented on the company. Barclays decreased their price objective on Charles River Laboratories International from $205.00 to $166.00 and set an “equal weight” rating on the stock in a report on Tuesday, February 18th. Robert W. Baird decreased their price objective on Charles River Laboratories International from $177.00 to $173.00 and set a “neutral” rating on the stock in a report on Thursday. Morgan Stanley decreased their price objective on Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating on the stock in a report on Wednesday, February 5th. CLSA cut Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 price objective on the stock. in a report on Monday, November 18th. Finally, JPMorgan Chase & Co. decreased their price objective on Charles River Laboratories International from $175.00 to $165.00 and set a “neutral” rating on the stock in a report on Thursday. Three equities research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and one has issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $195.71.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).